U.S. market Closed. Opens in 5 hours 52 minutes

AMLX | Amylyx Pharmaceuticals, Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-31
Revenue380.79M22.23M285.00K650.00K1.43M
Cost of Revenue25.44M2.99M52.00K24.59M11.90M
Gross Profit355.35M19.24M233.00K-23.94M-10.47M
Operating Expenses316.54M220.58M82.69M39.01M13.55M
Selling, General & Admin188.36M127.13M38.93M15.06M3.08M
Research & Development128.19M93.45M44.04M24.59M11.90M
Other Operating Expenses-660.00K3.74M-285.00K-650.00K-1.43M
Operating Income38.80M-201.34M-82.69M-39.01M-13.55M
Other Expenses / Income-660.00K3.74M-5.24M-3.27M-162.00K
Before Tax Income54.30M-197.60M-87.93M-42.28M-13.72M
Income Tax Expenses5.03M774.00K-52.00K2.56M1.10M
Net Income49.27M-198.38M-87.88M-44.84M-14.82M
Interest ExpensesN/A4.29MN/A2.29M1.28M
Basic Shares Outstanding67.23M66.51M57.86M56.47M56.47M
Diluted Shares Outstanding69.99M66.51M57.86M56.47M56.47M
EBITDA39.89M-201.34M-82.69M-38.72M-13.38M
EBITDA Margin10.48%-905.72%-29,013.33%-5,957.08%-938.22%
EBIT54.30M-193.31M-87.93M-39.99M-12.44M
EBIT Margin14.26%-869.59%-30,852.98%-6,152.62%-872.37%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙